FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/New Study Investigates Tirzepatide's Impact on Gastric Emptying in Type 1 Diabetes Patients
Retour à la bibliothèque de recherche

New Study Investigates Tirzepatide's Impact on Gastric Emptying in Type 1 Diabetes Patients

November 20, 2026
Share
Recherche émergente

Basé sur des recherches émergentes. Ces découvertes sont prometteuses mais nécessitent une validation supplémentaire.

À propos de cette analyse

Cet article est un résumé AI-assisté d'un élément de presse ou d'une annonce clinique récemment publié. Il vise à fournir une vue d'ensemble rapide et accessible pour la communauté de recherche en peptides. Pour une précision totale, consultez toujours l'original source ci-dessous.

New Study Investigates Tirzepatide's Impact on Gastric Emptying in Type 1 Diabetes Patients

A new clinical trial is set to explore how tirzepatide, a peptide therapy used for diabetes management, affects gastric emptying in adults with type 1 diabetes (T1D) who are also overweight or obese. The study, which has just been registered on ClinicalTrials.gov under the identifier NCT07951658, aims to provide valuable insights into how this medication interacts with existing insulin treatments and its potential benefits for managing diabetes.

Background

Type 1 diabetes is a chronic condition that requires lifelong management through insulin therapy. Recent advancements in peptide therapies have offered new treatment options, including tirzepatide, which combines glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonists. These combined actions make tirzepatide a promising tool for improving blood sugar control and weight management in people with diabetes.

However, understanding the full scope of how these new therapies interact with existing treatments is crucial. This is particularly true for gastric emptying rates, which can affect how quickly food moves through the stomach and impacts overall glucose levels. The current study aims to fill this knowledge gap by examining tirzepatide's effects on gastric emptying when used alongside insulin therapy.

Key Details

The trial will involve adults with type 1 diabetes who are also overweight or obese, focusing on those using automated insulin delivery (AID) systems for their regular treatment. Participants will receive weekly subcutaneous doses of tirzepatide as an additional therapy to their existing insulin regimen. The study is designed to be exploratory and non-randomized, meaning it will not compare different groups but rather observe the effects in a single group over time.

Researchers from the Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal are leading this Phase I trial. They aim to gather data on how varying doses of tirzepatide influence gastric emptying rates, potentially offering insights into optimal dosing strategies for future clinical applications. The study will take place across multiple centers and is currently recruiting participants.

Key Takeaways

  • Understanding Interactions: This study aims to clarify the interaction between tirzepatide and insulin therapy in managing type 1 diabetes.
  • Gastric Emptying Insights: Researchers will closely examine how different doses of tirzepatide affect gastric emptying rates, which could have implications for blood sugar control.
  • Patient Population Focus: The trial specifically targets individuals with T1D who are overweight or obese and use AID systems, providing tailored insights for this group.
  • Phase I Design: As a Phase I study, it focuses on safety and dosage determination rather than efficacy comparisons.

What This Means

For the peptide research community, this study represents an important step in understanding how new therapies like tirzepatide can be integrated into existing diabetes management protocols. By shedding light on gastric emptying dynamics, researchers may uncover additional benefits of these treatments beyond blood sugar regulation and weight loss. The findings could lead to more personalized treatment plans for patients with type 1 diabetes, enhancing overall health outcomes.

---

Source: ClinicalTrials.gov — Published 2026-11-20

This article is for informational purposes only and does not constitute medical advice.

Note de l'éditeur

Cette analyse a été générée à l'aide d'outils AI et revue par le service éditorial de Peptide Contacts. Bien que nous nous efforcions de maintenir une précision, le contenu généré par l'IA peut contenir des erreurs ou des omissions. Nous encourageons les lecteurs à vérifier les informations auprès de l'original source. source originale pour des détails complets, méthodologie et données.

Peptide Contacts fournit des résumés de recherche curatisés pour des fins d'information uniquement. Ce contenu ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant de prendre toute décision concernant votre santé.

Comments

Sign in to join the discussion

Cet article a été généré à l'aide d'IA et peut contenir des inexactitudes. Il est fourni pour des fins d'information uniquement et ne constitue pas un avis médical. Vérifiez toujours les informations auprès de l'original source et consultez un fournisseur de soins de santé qualifié avant de prendre toute décision concernant votre santé.